Onward Medical N.V. (ONWD.BR)
EUR 4.74
(-0.21%)
EUR 4.74
(-0.21%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 16.3 Million EUR | 16.89% |
| 2022 | 13.95 Million EUR | 5.75% |
| 2021 | 13.19 Million EUR | -68.5% |
| 2020 | 41.87 Million EUR | 24.35% |
| 2019 | 33.67 Million EUR | 92.79% |
| 2018 | 17.46 Million EUR | 64.58% |
| 2017 | 10.61 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 16.76 Million EUR | 0.0% |
| 2024 Q1 | 16.02 Million EUR | 5.03% |
| 2023 Q4 | 16.3 Million EUR | 0.0% |
| 2023 Q1 | 15.36 Million EUR | 10.16% |
| 2023 FY | 16.3 Million EUR | 16.89% |
| 2023 Q3 | 16.3 Million EUR | 6.11% |
| 2023 Q2 | 15.36 Million EUR | 0.0% |
| 2022 Q3 | 13.95 Million EUR | 2.88% |
| 2022 Q2 | 13.55 Million EUR | 0.0% |
| 2022 Q4 | 13.95 Million EUR | 0.0% |
| 2022 Q1 | 13.55 Million EUR | 2.78% |
| 2022 FY | 13.95 Million EUR | 5.75% |
| 2021 Q4 | 13.19 Million EUR | 0.0% |
| 2021 FY | 13.19 Million EUR | -68.5% |
| 2021 Q3 | 13.19 Million EUR | -80.97% |
| 2021 Q2 | 69.31 Million EUR | 0.0% |
| 2021 Q1 | 69.31 Million EUR | 65.51% |
| 2020 Q4 | 41.87 Million EUR | 0.0% |
| 2020 Q3 | 41.87 Million EUR | 0.0% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 41.87 Million EUR | 24.35% |
| 2019 FY | 33.67 Million EUR | 92.79% |
| 2018 FY | 17.46 Million EUR | 64.58% |
| 2017 FY | 10.61 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -1381.017% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 63.519% |
| Adocia SA | 4.54 Million EUR | -259.163% |
| Aelis Farma SA | 2.04 Million EUR | -696.191% |
| Biophytis S.A. | 3.11 Million EUR | -424.14% |
| Advicenne S.A. | 15.89 Million EUR | -2.579% |
| genOway Société anonyme | 5.51 Million EUR | -195.436% |
| IntegraGen SA | 642.28 Thousand EUR | -2438.768% |
| Medesis Pharma S.A. | 1.2 Million EUR | -1258.833% |
| Neovacs S.A. | 650 Thousand EUR | -2408.615% |
| NFL Biosciences SA | 39.2 Thousand EUR | -41493.756% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -274.291% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -731.799% |
| Sensorion SA | 1.24 Million EUR | -1214.035% |
| Theranexus Société Anonyme | 2.46 Million EUR | -562.652% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -318.317% |
| TheraVet SA | 1 Million EUR | -1529.624% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -136.114% |
| argenx SE | 15.35 Million EUR | -6.2% |
| BioSenic S.A. | 15.57 Million EUR | -4.707% |
| Celyad Oncology SA | 902 Thousand EUR | -1707.761% |
| DBV Technologies S.A. | 4.52 Million USD | -260.274% |
| Galapagos NV | 4.94 Million EUR | -229.814% |
| Genfit S.A. | 62.25 Million EUR | 73.807% |
| GeNeuro SA | 6.49 Million EUR | -151.159% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -4640.116% |
| Innate Pharma S.A. | 30.6 Million EUR | 46.725% |
| Inventiva S.A. | 25.61 Million EUR | 36.344% |
| MaaT Pharma SA | 5.42 Million EUR | -200.571% |
| MedinCell S.A. | 52.8 Million EUR | 69.117% |
| Nanobiotix S.A. | 41.66 Million EUR | 60.859% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -372.553% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 54.078% |
| Oxurion NV | 117 Thousand EUR | -13836.752% |
| Pharming Group N.V. | 123.65 Million EUR | 86.814% |
| Poxel S.A. | 40.14 Million EUR | 59.38% |
| GenSight Biologics S.A. | 1.04 Million EUR | -1455.916% |
| Transgene SA | 17 Thousand EUR | -95817.647% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.433% |
| Valneva SE | 132.76 Million EUR | 87.718% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |